MONTREAL, Aug. 27 /CNW Telbec/ - The Canadian Intellectual Property
Office granted Héma-Québec a patent(*) entitled "A New Method of Expanding Cord
Blood Cells" on July 14. Héma-Québec obtained a similar patent in the United
States on November 18, 2008.
Based on work performed at Héma-Quebec's research and development
laboratories, this patent concerns a cellular culture method that permits
faster and more efficient expansion of cord blood stem cells. In addition,
this process aims to increase the performance of a specific type of blood
platelet-producing cell. The platelet yield obtained by applying this cell
culture method is therefore improved.
This new process will aid in patients' post-transplant recovery through
increased platelet production. Cord blood stem cells are used in certain types
of treatments to perform transplants on patients with often-fatal diseases,
such as leukemia, serious immunodeficiency, or severe anemia.
"This US/Canada patent illustrates the expertise acquired by
Héma-Québec's research and development team in cord blood stem cell culture
and in-vitro stem cell production," says Yves Blais, Vice-President, Research
and Development at Héma-Québec. "We are confident this new process will
attract attention from potential partners and companies interested in
developing cell therapy products and technologies."
(*)Canadian patent No.2,562,760 -
(*)US patent No.7,452,662 -
Héma-Québec aims to efficiently provide adequate quantities of safe,
optimal blood components, substitutes, human tissues and cord blood to meet
the needs of all Quebecers; provide and develop expertise along with
specialized and innovative services and products in the fields of transfusion
medicine and human tissue transplantation.
For further information:
For further information: Valérie Legault, Information Officer, (514)
832-0871, email@example.com; www.hema-quebec.qc.ca; Source: Manon
Pepin, Vice-President, Public Affairs and Marketing